AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Capoten was an important new medical discovery for the treatment of patients with high blood pressure. Bristol-Myers merged with Squibb in ... bipolar disorder, or schizophrenia, had sales of ...

Try Now>> See the top stocks recommended by analysts >> Read More on BMY: Bristol-Myers Squibb NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

one company that might be well-poised to benefit is Bristol-Myers Squibb Company (BMY). BMY spiked 10.5% today on the heels ...

Bristol-Myers Squibb has decided to gamble on the ... For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine D2 receptors, but KarXT is one ...